Post procedural infection adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2005 to June 2026, FDA received 8,006 adverse event reports that record the MedDRA preferred term Post procedural infection. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 610 reports in the 12 months to June 2026 and 547 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 874 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 610 (under 0.1%) record this term. Reports for patients aged 45 to 64 were 28.9% of the reports that record this term and 20% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 148 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Post procedural infection name as a suspect product, in order of name
Drug	Class	Reports with this term
Abatacept	Selective T cell costimulation modulator	66
Actemra	Interleukin-6 receptor antagonist	114
Adalimumab	Tumor necrosis factor blocker	60
Alendronate sodium	Bisphosphonate	20
Alvesco		15
Ambrisentan	Endothelin receptor antagonist	19
Amlodipine	Calcium channel blocker	15
Arava	Antirheumatic agent	12
Atorvastatin		17
Aubagio	Pyrimidine synthesis inhibitor	17
Avonex	Interferon beta	73
Baclofen	gamma-Aminobutyric acid-ergic agonist	27
Bevacizumab	Vascular endothelial growth factor inhibitor	11
Bimekizumab		11
Boniva		10
Bss	Osmotic laxative	16
Byetta	GLP-1 receptor agonist	11
Cabometyx	Kinase inhibitor	23
Candesartan	Angiotensin 2 receptor blocker	23
Candesartan cilexetil	Angiotensin 2 receptor blocker	11
Capecitabine	Nucleoside metabolic inhibitor	13
Carbidopa levodopa	Aromatic amino acid	10
Celebrex	Nonsteroidal anti-inflammatory drug	19
Certolizumab pegol	Tumor necrosis factor blocker	71
Cimzia	Tumor necrosis factor blocker	56
Ciprofloxacin	Fluoroquinolone antibacterial	21
Cosentyx	Interleukin-17A antagonist	117
Creon		17
Cuvitru	Human immunoglobulin G	11
Cyclophosphamide	Alkylating drug	10
Cyclosporine	Calcineurin inhibitor immunosuppressant	11
Cytarabine	Nucleoside metabolic inhibitor	11
Dexamethasone	Corticosteroid	15
Dianeal		25
Dianeal Low Calcium		60
Dianeal Low Calcium Peritoneal Dialysis Solution with Dextrose		87
Diltiazem		15
Docetaxel	Microtubule inhibitor	24
Dovato	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	13
Doxorubicin	Anthracycline topoisomerase inhibitor	15
Duodopa		26
Dupixent	Interleukin-4 receptor alpha antagonist	113
Eligard	Gonadotropin releasing hormone receptor agonist	15
Eliquis	Factor Xa inhibitor	27
Enbrel	Tumor necrosis factor blocker	543
Entresto	Angiotensin 2 receptor blocker	21
Entyvio	Integrin receptor antagonist	19
Etanercept	Tumor necrosis factor blocker	22
Extraneal	Osmotic laxative	32
Flovent	Corticosteroid	13
Fluorouracil	Nucleoside metabolic inhibitor	18
Fluoxetine	Serotonin reuptake inhibitor	14
Folic acid		15
Forteo	Parathyroid hormone analog	45
Fosamax	Bisphosphonate	56
Fosamax Plus D		12
Furosemide	Loop diuretic	17
Gabapentin	Anti-epileptic agent	23
Gilenya	Sphingosine 1-phosphate receptor modulator	11
Humalog	Insulin analog	34
Human immunoglobulin g	Human immunoglobulin G	82
Human Immunoglobulin G Hyaluronidase Recombinant Human		16
Humira		1,156
Hydrocortisone	Corticosteroid	19
Hydroxychloroquine	Antimalarial	11
Ibrance	Kinase inhibitor	20
Imatinib	Kinase inhibitor	10
Imbruvica	Kinase inhibitor	61
Imraldi		13
Inflectra	Tumor necrosis factor blocker	85
Infliximab	Tumor necrosis factor blocker	81
Insulin glargine	Insulin analog	14
Jakafi	Janus kinase inhibitor	42
Kardegic		11
Lamivudine	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	12
Lantus	Insulin analog	19
Leflunomide	Antirheumatic agent	43
Lenalidomide	Thalidomide analog	23
Linagliptin	Dipeptidyl peptidase 4 inhibitor	18
Lioresal (baclofen)	gamma-Aminobutyric acid-ergic agonist	19
Lyrica		23
Mepolizumab	Interleukin-5 antagonist	15
Methotrexate	Folate analog metabolic inhibitor	172
Methotrexate sodium	Folate analog metabolic inhibitor	62
Methylprednisolone	Corticosteroid	10
Metronidazole	Nitroimidazole antimicrobial	18
Mirena	Progestin	26
Morphine	Opioid agonist	23
Morphine sulfate	Opioid agonist	21
Mycophenolate mofetil	Antimetabolite immunosuppressant	25
Ocrevus	CD20-directed cytolytic antibody	14
Ofev	Kinase inhibitor	21
Omalizumab	Anti-IgE	27
Opdivo	Programmed death Receptor-1 blocking antibody	13
Opsumit	Endothelin receptor antagonist	24
Orencia	Selective T cell costimulation modulator	78
Otezla	Phosphodiesterase 4 inhibitor	20
Oxaliplatin	Platinum-based drug	14
OxyContin	Opioid agonist	24
Ozempic	GLP-1 receptor agonist	18
Pantoprazole	Proton pump inhibitor	16
Pembrolizumab	Programmed death Receptor-1 blocking antibody	13
Pertuzumab	HER2/neu receptor antagonist	12
Plaquenil	Antimalarial	20
Pomalyst	Thalidomide analog	33
Prednisolone	Corticosteroid	20
Prednisone	Corticosteroid	117
Prolia	RANK ligand inhibitor	83
Rebif	Interferon beta	52
Remicade	Tumor necrosis factor blocker	263
Repatha	PCSK9 inhibitor	20
Revlimid	Thalidomide analog	70
Rinvoq	Janus kinase inhibitor	234
Rituxan	CD20-directed cytolytic antibody	19
Rituximab	CD20-directed cytolytic antibody	71
Ruxience	CD20-directed cytolytic antibody	11
Sandostatin	Somatostatin analog	23
Sandostatin LAR Depot		36
Simponi	Tumor necrosis factor blocker	196
Singulair	Leukotriene receptor antagonist	14
Skyrizi	Interleukin-23 antagonist	208
Soliris	Complement inhibitor	13
Spinraza	Antisense oligonucleotide	17
Stelara	Interleukin-12 antagonist	146
Sulfasalazine	Aminosalicylate	22
Tacrolimus	Calcineurin inhibitor immunosuppressant	32
Taltz	Interleukin-17A antagonist	18
Tecfidera		54
Teduglutide	GLP-2 analog	15
Theophylline	Methylxanthine	13
Tiotropium bromide	Anticholinergic	23
Tivicay	Human immunodeficiency virus integrase strand transfer inhibitor	13
Tracleer	Endothelin receptor antagonist	10
Tramadol hydrochloride	Opioid agonist	11
Trastuzumab	HER2/neu receptor antagonist	14
Trulicity	GLP-1 receptor agonist	20
Tymlos		14
Tysabri	Integrin receptor antagonist	134
Uptravi	Prostacyclin receptor agonist	13
Vancomycin	Glycopeptide antibacterial	12
Vedolizumab	Integrin receptor antagonist	161
Venclexta	BCL-2 inhibitor	19
Xarelto	Factor Xa inhibitor	23
Xeljanz	Janus kinase inhibitor	180
Xgeva	RANK ligand inhibitor	12
Xolair	Anti-IgE	24
Xyrem	Central nervous system depressant	36
Zometa		10

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 48 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Post procedural infection name, in order of name
Class	Reports with this term
Angiotensin 2 receptor blocker	65
Anti-epileptic agent	25
Anti-IgE	51
Anticholinergic	29
Antimalarial	40
Antimetabolite immunosuppressant	27
Antirheumatic agent	55
Bisphosphonate	85
Calcineurin inhibitor immunosuppressant	50
CD20-directed cytolytic antibody	122
Central nervous system depressant	42
Corticosteroid	226
Endothelin receptor antagonist	59
Factor Xa inhibitor	63
Fluoroquinolone antibacterial	32
Folate analog metabolic inhibitor	234
gamma-Aminobutyric acid-ergic agonist	54
GLP-1 receptor agonist	66
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	25
HER2/neu receptor antagonist	38
Human immunoglobulin G	111
Insulin analog	75
Integrin receptor antagonist	314
Interferon beta	125
Interleukin-12 antagonist	152
Interleukin-17A antagonist	135
Interleukin-23 antagonist	216
Interleukin-4 receptor alpha antagonist	113
Interleukin-6 receptor antagonist	123
Janus kinase inhibitor	467
Kinase inhibitor	200
Leukotriene receptor antagonist	25
Microtubule inhibitor	28
Nitroimidazole antimicrobial	27
Nonsteroidal anti-inflammatory drug	49
Nucleoside metabolic inhibitor	50
Opioid agonist	114
Osmotic laxative	57
Parathyroid hormone analog	47
Progestin	30
Programmed death Receptor-1 blocking antibody	38
Prostacycline vasodilator	28
Proton pump inhibitor	26
RANK ligand inhibitor	95
Selective T cell costimulation modulator	144
Somatostatin analog	29
Thalidomide analog	126
Tumor necrosis factor blocker	1,402

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Post procedural infection, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Post procedural infection
Age	Reports	Share
Under 2	14	0.2%
2 to 11	28	0.3%
12 to 17	59	0.7%
18 to 44	900	11.2%
45 to 64	2,313	28.9%
65 to 74	1,169	14.6%
75 and over	675	8.4%
Age not given	2,848	35.6%

Sex of the patient in the reports that record Post procedural infection
Sex	Reports	Share
Female	4,793	59.9%
Male	2,637	32.9%
Unknown or not given	576	7.2%

Age and sex are as the report gives them. 58.7% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Post procedural infection: adverse event reports that record this term. https://reportedreactions.com/reaction/post-procedural-infection/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Post procedural infection mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page